Website The University of Manchester
Details
Systemic sclerosis (SSc), or scleroderma, is a rare rheumatological disease characterised by immune dysregulation, vascular dysfunction, and progressive tissue fibrosis affecting the skin and internal organs. SSc has among the highest mortality rates of the rheumatic diseases, has no known cure, and is associated with substantial chronic morbidity and impaired quality of life. Increasing evidence suggests that disturbances of local microbial communities may contribute to inflammation, immune activation, infection susceptibility, impaired healing, and disease expression in SSc, although these relationships remain poorly understood.
Key clinical manifestations provide clear opportunities to investigate host–microbiome interactions. Approximately half of patients develop painful digital ulcers, which are often slow to heal and prone to recurrent colonisation or infection by organisms such as Staphylococcus aureus and enteric bacteria. Gastrointestinal involvement affects more than 90% of patients and may involve the entire gastrointestinal tract; dysmotility can predispose to small intestinal bacterial overgrowth, malabsorption, nutritional compromise, and reduced quality of life. Orofacial involvement is also common, affecting the lips, oral mucosa, salivary glands, and perioral tissues. Xerostomia, frequently associated with overlapping Sjögren’s syndrome, may contribute to dental disease, accelerated caries, mucosal abnormalities, and altered oral microbial ecology.
This project will use molecular microbiology, microbiome profiling, culture-based analysis, and bioinformatics to investigate relationships between microbial communities, infection, inflammation, and disease expression in SSc. Patients will be recruited through Salford Royal Hospital, typically alongside routine outpatient appointments within the established SSc clinical service. Relevant demographic, clinical, imaging, and disease-related data will be collected alongside microbiological sampling from relevant anatomical sites, potentially including digital ulcers, skin, oral sites, saliva, and gastrointestinal-associated samples. The work will build on supervisory expertise in applied microbiology, wound infection, biofilms, antimicrobial technologies, microbiome science, clinical rheumatology, and host–microbiome interactions.
Eligibility
Candidates are expected to hold, or be about to obtain, a minimum upper second-class honours degree (or equivalent) in microbiology, biomedical sciences, medicine, immunology, bioinformatics, molecular biology, or a related discipline. Candidates with experience or interest in microbiome science, clinical microbiology, bioinformatics, AI/data science, rheumatology, or translational biomedical research are particularly encouraged to apply.
Before you Apply
Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.
How to Apply
To be considered for this project you MUST submit a formal online application form – on the application form select PhD Medical Microbiology Programme. Full details on how to apply can be found on the Website: How to apply for postgraduate research at The University of Manchester
If you have any queries regarding making an application please contact our admissions team FBMH.doctoralacademy.admissions@manchester.ac.uk
Equality, Diversity and Inclusion
Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website: Equality, diversity and inclusion (EDI | Postgraduate Research | Biology, Medicine and Health | University of Manchester
Funding Notes
Applications are invited from self-funded students. This project has a Band 3 (high) fee. Details of our different fee bands can be found on our website https://www.bmh.manchester.ac.uk/study/research/fees/
References
1. Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med (Lond). 2019;80(9):530-536.
2. Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol. 2020;16(4):208-221.
3. Abbas N, Willmott T, Campbell PM, Singh G, Basu M, Reid F, McBain AJ. Distinct microbiome profiles on vaginally inserted polypropylene midurethral mesh slings compared to vaginal, urinary, and skin microbiomes. Appl Environ Microbiol. 2025;91(7).
4. Campbell PM, Willmott T, Humphreys GJ, Piscoran O, Chea H, Summers AM, Konkel JE, Knight CG, Augustine T, McBain AJ. Transplantation impacts on the oral microbiome of kidney recipients and donors. Front Microbiomes. 2023;3:1258290.
5. Kim S, Park HJ, Lee SI. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential. Int J Mol Sci. 2022;23(24):16154
Want fewer missed deadlines?
Pick WhatsApp or Telegram, then follow a channel (Graduate → Post-PhD).